A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate

Clinical Pharmacokinetics

Volumn 47, Issue 8, 2008, Pages 543-552

  Bronner, Felix ^a   Slepchenko, Boris M ^a   Pennick, Michael ^b   Damment, Stephen J P ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Shire Pharmaceuticals   (United Kingdom)

Author keywords

Bone; Hyperphosphataemia; Lanthanum carbonate, pharmacokinetics; Pharmacokinetic modelling; Phosphate binders, pharmacokinetics; Renal failure

Indexed keywords

CALCIUM; LANTHANUM; LANTHANUM CARBONATE; LANTHANUM CHLORIDE; METAL DERIVATIVE; PHOSPHATE BINDING AGENT;

ADULT; ARTICLE; BLOOD LEVEL; BONE; CALCIUM INTAKE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG INFUSION; DRUG METABOLISM; HEMODIALYSIS PATIENT; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERPHOSPHATEMIA; INTESTINE ABSORPTION; LONG TERM CARE; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; BONE AND BONES; CALCIUM; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; LANTHANUM; MODELS, BIOLOGICAL; PHOSPHATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TIME FACTORS;

EID: 47049102297     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847080-00004     Document Type: Article

References (51)

1. Hruska KA, Lederer ED. Hyperphosphatemia and hypophosphatemia. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington DC: American Society of Bone and Mineral Research, 2003: 296-306
2. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 Aug; 15 (8): 2208-18
3. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004 May-Jun; 17 (3): 209-16
4. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998 Apr; 31 (4): 607-17
5. Rufino M, de Bonis E, Martin M, et al. Is it possible to control hyperphosphataemia with diet, without inducing protein malnutrition? Nephrol Dial Transplant 1998; 13 Suppl. 3: 65-7
6. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003; 21 (4-5): 318-26
7. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003; 26 (15): 1093-115
8. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986 Jul 17; 315 (3): 157-61
9. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 2003 Sep; 14 (9 Suppl. 4): S310-4
10. Vatticuti R, Towler DA. Osteogenic vascular calcification: an early perspective. Amer J Physiol Endocrinol Metab 2004; 286: E686-96
11. Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000 Jul; 15 (7): 1014-21
12. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl. 3): 1-201
13. Bronner F. Metals in bone: aluminum, boron, cadmium, chromium, lead, silicon, and strontium. In: Bilezekian JP, Raisz LR, Rodan GA, editors. Principles of bone biology. 2nd ed. New York: Academic Press, 2002: 359-69
14. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002; 17 Suppl. 2: 21-4
15. Wills MR, Savory J. Aluminum and chronic renal failure: sources, absorption, transport, and toxicity. Crit Rev Clin Lab Sci 1989; 27 (1): 59-107
16. Sedman AB, Alfrey AC, Miller NL, et al. Tissue and cellular basis for impaired bone formation in aluminum-related osteomalacia in the pig. J Clin Invest 1987 Jan; 79 (1): 86-92
17. Genzyme Corporation. Renagel tablets (sevelamer hydrochloride) 400 & 800 mg [prescribing information]. Cambridge (MA): Genzyme Corporation, 2004
18. Nolan C, Qunibi W, McCarron D. High incidence of intestinal obstruction and perforation during treatment with sevelamer HCL [abstract]. J Am Soc Nephrol 2006; 17: 358A
19. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007 Oct; 96 (10): 2818-27
20. Hutchison AJ, Maes B, Vanwalleghem J, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100 (1): c8-c19
21. Pennick M, Dennis K, Damment SJ. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacol 2006 Jul; 46 (7): 738-46
22. Schafer U, Jahreis G. Exposure, bioavailability, distribution and excretion of aluminum and its toxicological relevance to humans. Trace Elements and Electrolytes 2006; 23 (3): 162-72
23. Priest ND, Newton D, Day JP, et al. Human metabolism of aluminium-26 and gallium-67 injected as citrates. Hum Exp Toxicol 1995 Mar; 14 (3): 287-93
24. Damment SJP, Gill M. The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol®), a new non-aluminium, non-calcium phosphate binder [abstract]. J Am Soc Nephrol 2003; 14: 204A
25. Yang Z, Schryvers D, Roels F, et al. Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc 2006 Aug; 223 (Pt 2): 133-9
26. Floren C, Tekaya L, Escaig F, et al. Analytical microscopy observations of rat enterocytes after oral administration of soluble salts of lanthanides, actinides and elements of group III-A of the periodic chart. Cell Mol Biol (Noisy-le-grand) 2001 May; 47 (3): 419-25
27. Behets GJ, Verberckmoes SC, Oste L, et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005 May; 67 (5): 1830-6
28. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003 Jun; (85): S73-8
29. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005 Dec; 64 (6): 428-37
30. Damment SJ. Enlightenment on liver lanthanum exposure. Kidney Int 2006 Oct; 70 (7): 1372-3; author reply 1373
31. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005 Dec; 68 (6): 2809-13
32. Ben-Dov IZ, Pappo O, Sklair-Levy M, et al. Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant 2007 Feb; 22 (2): 362-8
33. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006 Aug; 21 (8): 2217-24
34. Aubert JP, Bronner F, Richelle LJ. Quantitation of calcium metabolism. Theory J Clin Invest 1963 Jun; 42: 885-97
35. Bronner F. Dynamics and function of calcium. In: Comar CL, Bronner F, editors. Mineral metabolism: an advanced treatise. Vol. 2a. New York: Academic Press, 1964: 341-444
36. Bronner F. Kinetic and cybernetic analysis of calcium metabolism. In: Irving JT, editor. Calcium and phosphorus. New York and London: Academic Press, 1973: 149-86
37. Bronner F, Harris RS, Maletskos SJ, et al. Studies in calcium metabolism: the fate of intravenously injected radiocalcium in human beings. J Clin Invest 1956; 42: 898-905
38. Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 2003; 42 (10): 863-81
39. Altmann P, Barnett ME, Finn WF. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007 Feb; 71 (3): 252-9
40. Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006; 102 (2): c61-71
41. Malluche HH, Wilson R. A 2-year randomized, comparator-controlled trial investigating the effect of lanthanum carbonate on bone [abstract A297]. In: 3rd World Congress of Nephrology; 2005 Jun 26-30; Singapore.
42. Heaney RP, Bauer GC, Bronner F, et al. A normal reference standard for radio-calcium turnover and excretion in humans. J Lab Clin Med 1964 Jul; 64: 21-8
43. Damment SJP, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol Lett 2007 Jun 15; 171 (1-2): 69-77
44. Marshall JH, Lloyd EL, Rundo J, et al. Alkaline earth metabolism in adult man. Health Physics 1973; 24: 129-221
45. Bronner F. Calcium. In: Sunde RA, editor. Handbook of nutritionally essential mineral elements. New York: Marcel Dekker, 1997: 13-61
46. Simmons DJ, Grynpas MD. Mechanisms of bone formation in vivo. In: Hall BK, editor. Bone. Vol. 1: the osteoclast and osteocyte. Caldwell (NJ): Telford Press, 1990: 193-302
47. Mayer I, Layani JD, Givan A, et al. La ions in precipitated hydroxyapatites. J Inorg Biochem 1999 Apr; 73 (4): 221-6
48. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006 Mar; 65 (3): 191-202
49. Malluche HH, Faugere M, Wang G, et al. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years [abstract]. J Am Soc Nephrol 2004; 15: 270A
50. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006 Aug; 36 Suppl. 2: 51-62
51. Mathew S, Davies M, Lund R, et al. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006 Aug; 36 Suppl. 2: 43-50